Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px

Product › Details

PARP inhibitor

	Next higher product group	cancer drug
	Status	2005-12-23 development p1 existent
	Organisation	AstraZeneca plc (LSE: AZN)
	Group	AstraZeneca (Group)
	Organisation 2	Kudos Pharmaceuticals Ltd.
	Today	AstraZeneca (Group)
	Group	AstraZeneca (Group)

Record changed: 2023-10-30

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for PARP inhibitor

[1] Merck KGaA. (10/30/23). "Press Release: Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate [Not intended for US-, Canada- or UK-based media]". Darmstadt...
[2] Ariceum Therapeutics GmbH. (6/1/23). "Press Release: Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd". Berlin....
[3] Merck & Co., Inc.. (12/21/22). "Press Release: Lynparza (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer". Rahway, NJ....
[4] Merck KGaA. (9/21/22). "Press Release: Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor [ Not intended for US- or Canada- and UK-based media ]". Darmstadt....
[5] Foundation Medicine, Inc.. (8/26/20). "Press Release: FDA Approves Foundation Medicine's FoundationOne Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer". Cambridge,...
[6] AstraZeneca plc. (10/24/19). "Press Release: Year-to-Date and Q3 2019 Results"....
[7] Theragnostics Ltd.. (9/5/19). "Press Release: Theragnostics Signs Agreement with AstraZeneca". London....
[8] GlaxoSmithKline plc. (6/24/19). "Press Release: U.S. Food and Drug Administration Accepts GSK’s Application for Zejula (niraparib) in Late Stage Ovarian Cancer with Priority Review". London....
[9] GlaxoSmithKline plc. (1/22/19). "Press Release: GSK Completes Acquisition of Tesaro, an Oncology Focused Biopharmaceutical Company". London....
[10] Ribon Therapeutics, Inc.. (1/4/19). "Press Release: Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer". Lexington, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]